CClinicalTrials.gg
RecruitingNCT06648421Updated Oct 18, 2024

Reference Values for the One Repetition Maximum Test of Knee Extensors for Brazilians.

An observational study in Healthy, sponsored by Universidade Estadual de Londrina. Recruiting at 1 site in Brazil. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-18.

Sponsored by Universidade Estadual de Londrina · Observational

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
72
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Muscle strength is important for health and can affect how well people live, even increasing the risk of death in adults and older people. The one-repetition maximum (1RM) test is relatively easy compared to other tests and is commonly used to measure muscle strength in various groups, including healthy individuals and those with chronic diseases. It assists in prescribing resistance training and understanding training results. Knee extensors, especially the quadriceps femoris, are often studied because they play a key role in standing and walking. However, there are no standard reference values or equations for measuring knee extensors using the 1RM test. The existing methods rely on the evaluator's judgment, making them hard to replicate and standardize. The goal of this study is to provide reference equations and values for the 1RM of knee extensors and to establish a standardized methodology for the test.

Read the detailed description

The project consists of two phases: in order to develop the final standardized 1RM protocol, a pilot study (phase 1) will be conducted to identify the best objective load to start the 1RM attempts. The protocol will then be defined according to the results of the pilot study, and the main study (phase 2) will be initiated using this protocol.

The one-repetition maximum test (1RM) will be conducted using a leg extension machine (MacSport, Sigma). This test aims to determine the maximum weight that can be lifted in a single movement by the tested muscle group (in this study, knee extensors) through its full range of motion and without compensatory movements. The knees should be aligned with the axis of the equipment (adjust the backrest if necessary), and hands should firmly grip the handles. The equipment will be set so that individuals start the knee extension from a 90 degree flexion and extend until reaching a 0 degree flexion. Standardized verbal encouragement will be given during the tests.

All recruited individuals, both those participating in the pilot study (phase 1) and those in the main study (phase 2), will be evaluated at two different moments. In the first evaluation (pilot study test 1, or pilot study T1), participants will be assessed for anthropometric data, presence of comorbidities, self-reported regular physical activity, cognitive screening and knee extensor muscle strength using the 1RM test, following the protocol proposed by the authors (details below). Specifically for the pilot study, which is a methodological study aimed at identifying the best initial load for the first 1RM attempt, three initial load options based on body weight (40%, 60%, and 80% of body weight) will be randomly assigned via envelopes. The pilot study will include 72 individuals in total, distributed across six age groups with an average interval of ten years (i.e., 18-29, 30-39, 40-49, 50-59, 60-69 and 70-80 years). Each age group will have 12 participants, with four performing the first 1RM attempt at 40% of body weight (two men and two women), another four at 60% of body weight (two men and two women), and the remaining four at 80% of body weight (two men and two women). This way, participants will be evenly distributed among age groups, gender and percentage of body weight for the initial 1RM attempt. In the assessment of the pilot study (pilot study T2), 48-72 hours after the first assessment pilot study T1, individuals will be re-evaluated for knee extensor strength (following the same protocol and the same percentage of body weight as in pilot study T1) to investigate the reproducibility and familiarization (e.g., learning affect) of the test.

The porposed protocol for the pilot study will follow this sequence: (1) warm-up with a set of 10 repetitions with a light load (20% of body weight); (2) two minutes of rest; (3) the frist attempt will be with the percentage of body weight randomly chosen before the start of the pilot (i.e., 40%, 60% or 80% of body weight); (4) the load progression will be based on the Likert scale of difficulty from 1 to 5 (1-Very easy, 2-Easy, 3-Moderate, 4-Very difficult, and 5-Extremely difficult); responses from 1 to 3 will have an increment of 20% of the last load, and responses from 4 to 5 will have an increment of 10% of the last load. Individuals will have two minutes of rest between each progression; (5) if the attempt is unsuccessful, the load should be decreased by 5% or 10%; upon success, this will be the 1RM value, and upon failure, the 1RM will be the last value successfully lifted; (6) the 1RM value should ideally be obtained in 4 to 6 attempts, provided that the last attempt is not the highest value. As mentioned earlier, after 48-72 hours, individuals will perform the pilot study T2 following the same protocol and initial load drawn in pilot study T1. The best initial load for the 1RM test will be the one that allows reaching the highest 1RM value in the fewest attempts in the best tests conducted in pilot study T1 and pilot study T2, as long as they fall within the range of 4 to 6 attempts.

After the completion of the pilot study with the result of the best initial load for the 1RM test, the main study will begin and follow the same protocol previously proposed. However, it will use the best percentage of body weight identified as the ideal initial load in the pilot study during both main study tests (main study T1 and main study T2). In both the pilot and main studies, the same evaluator should perform the test in both T1 and T2, allowing for the analysis of intra-evaluator reproducibility and avoiding potential inter-evaluator bias. The 1RM value used for analysis will be the highest value obtained from the evaluations in main study T1 and main study T2.

The sample size will be calculated based on the pilot study. The variable used for the calculation will be knee extensor strength, as this is the main outcome of the study. A power of 80% and an alpha of 0.05 will be adopted.

Microsoft Excel 2010 (Microsoft, USA) and SPSS 21.0 version (IBM, USA) will be used for data tabulation and statistical analysis, respectively. The Shapiro-Wilk test will be used for the analysis of normality in data distribution. Data with normal distribution will be described as mean ± standard deviation and statistically treated with parametric tests, whereas data with non-normal distribution will be described as median [interquartile range 25-75%] and statistically treated with non-parametric tests. To identify the best initial load for the 1RM test in the pilot study and to compare different age groups, one-way ANOVA or Kruskal-Wallis test with Dunn's post hoc test will be used when necessary. Pearson or Spearman coefficients will be used to identify simple correlations between the 1RM test and anthropometric variables, while multiple linear regression analysis will be used to establish reference equations. A value of P\<0.05 will be adopted as statistical significance, except for the multiple linear regression model where variables showing a correlation with 1RM of knee extensors up to P\<0.20 will be included in the model.

02

Conditions studied

  • Healthy

Keywords

  • Muscle Strength
  • Isotonic Contraction
  • Reference Values
03

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Apparently healthy individuals from the local community, as well as students, employees of the involved institution and their families will be recruited, provided they do not have any condition that may limit the performance of the knee extensor muscle strength testing and/or do not have contraindications for its execution.

Inclusion criteria

  • Individuals aged between 18-80 years of both sexes;
  • Absence of any condition (e.g., orthopedic, neuromuscular, cardiorespiratory) that may limit the assessment or directly interfere in its results.

Exclusion criteria

Exclusion Criteria:

  • Failure to complete the proposed assessments for any reason;
  • A score on the Mini-Mental State Examination lower than18 for illiterate individuals and lower than 24 for literate individuals;
  • Body mass index (BMI) lower than 18 kg/m2 and higher than 40 kg/m2;
  • The manifestation of the desire to leave the study at any time for any reason.
04

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
72 participants (estimated)
Patient registry
No

Groups and cohorts

  • Healthy individuals aged 18 to 80 years old

    Healthy individuals aged 18 to 80 years old

05

What researchers measure

Primary outcomes

  1. Muscle strength of knee extensors

    One repetition maximum test (1RM) of knee extensors

    Time frame: 1 week

Secondary outcomes

  1. Weight

    A calibrated digital scale will be used to assess the weight of the individuals in kilograms.

    Time frame: 1 week

  2. Height

    Height will be measured in meters using a vertical stadiometer. Weight and height will be combined to report BMI in kg/m\^2

    Time frame: 1 week

  3. Lower limb measurements

    A measuring tape will be used to measure the length of the tíbia and the thigh circumference, measured 15 cm above the upper edge of the patela.

    Time frame: 1 week

  4. Comorbidities

    The presence of comorbidities will be assessed to characterize the sample using the Charslon Comorbidity Index. This index consists of self reported comorbidities that are categorized from 1 to 6 based on the adjusted risk of mortality. The sum of all weights results in a single score for each individual. Higher scores indicate a greater risk, and a score of zero indicates that no comorbidity was reported

    Time frame: 1 week

  5. Physical Activity

    Individuals will be asked about their physical activity, type, frequency, duration and how long they have been engaging in this activity using a simple unpublished questionnaire developed by the authors.

    Time frame: 1 week

  6. Cognitive Screening

    Cognitive screening will be conducted using the Mini-Mental State Examination (MMSE). This is a simple and easy to administer questionnaire, commmonly used in clinical and research contexts. The MMSE consists of questions grouped into seven categories to assess specific cognitive functions. The score can range from 0 to 30 points. In the Brazilian population, the suggested cutoff point for normal cognitive capacity is 18 points for illiterate individuals and 24 points for literate individuals.

    Time frame: 1 week

06

Study locations

1 of 1 sites recruiting
  • Health Sciences Center of the State University of Londrina
    Londrina, Paraná 86038-350, Brazil
    Recruiting
07

Registry details

Key details

Study ID
NCT06648421
Lead sponsor
Universidade Estadual de Londrina
Responsible party
Fabio Pitta, PhD (Principal Investigator, Universidade Estadual de Londrina) — Principal investigator
First posted
Oct 18, 2024
Start date
Jul 7, 2024
Primary completion
Feb 2, 2026 (estimated)
Completion
Apr 6, 2026 (estimated)
Last update
Oct 18, 2024

Study contacts

Fabio O Pitta, PhD
Contact
fabiopitta@uel.br
+5543991015480
Fabio O Pitta, PhD
principal investigator · State University of Londrina

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion